Topoisomerase II and leukemia

Annals of the New York Academy of Sciences

Volumn 1310, Issue 1, 2014, Pages 98-110

  Pendleton, Maryjean ^a   Lindsey, R Hunter ^a   Felix, Carolyn A ^b   Grimwade, David ^c   Osheroff, Neil ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acute myeloid leukemia; Acute promyelocytic leukemia; Anticancer drug; Chromosomal translocation; Topoisomerase II poison

Indexed keywords

CURCUMIN; CYTOCHROME P450 3A4; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIGALLOCATECHIN; ETOPOSIDE; GENISTEIN; MITOXANTRONE; TURMERIC;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 17Q; CHROMOSOME 3P; CHROMOSOME DAMAGE; CHROMOSOME TRANSLOCATION; CONFORMATIONAL TRANSITION; DNA STRAND BREAKAGE; HOX GENE; HUMAN; LEUKEMIA; MITOSIS; NONHUMAN; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; TEA;

ACUTE MYELOID LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; ANTICANCER DRUG; CHROMOSOMAL TRANSLOCATION; TOPOISOMERASE II POISON;

ANIMALS; ANTINEOPLASTIC AGENTS; CATECHIN; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME BREAKAGE; CURCUMIN; DNA TOPOISOMERASES, TYPE II; GENISTEIN; HUMANS; INFANT; LEUKEMIA; NEOPLASMS, SECOND PRIMARY; TRANSLOCATION, GENETIC;

EID: 84896305694     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12358     Document Type: Article

References (149)

1. McClendon, A.K. & N. Osheroff. 2007. DNA topoisomerase II, genotoxicity, and cancer. Mutat. Res. 623: 83-97.
2. Deweese, J.E. & N. Osheroff. 2009. The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res. 37: 738-748.
3. Nitiss, J.L. 2009. DNA topoisomerase II and its growing repertoire of biological functions. Nat. Rev. Cancer 9: 327-337.
4. Liu, Z., R.W. Deibler, H.S. Chan & L. Zechiedrich. 2009. The why and how of DNA unlinking. Nucleic Acids Res. 37: 661-671.
5. Vos, S.M., E.M. Tretter, B.H. Schmidt & J.M. Berger. 2011. All tangled up: how cells direct, manage and exploit topoisomerase function. Nat. Rev. Mol. Cell. Biol. 12: 827-841.
6. Gentry, A.C. 2013. "DNA topoisomerases: type II." In The Encyclopedia of Biological Chemistry. W.J. Lennarz and M.D. Lane, Eds.: 163-168. Waltham, MA: Academic Press.
7. Nitiss, J.L. 2009. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 9: 338-350.
8. Pommier, Y. & C. Marchand. 2012. Interfacial inhibitors: targeting macromolecular complexes. Nat. Rev. Drug Discov. 11: 25-36.
9. Pommier, Y. 2013. Drugging topoisomerases: lessons and challenges. ACS Chem. Biol. 8: 82-95.
10. Felix, C.A., C.P. Kolaris & N. Osheroff. 2006. Topoisomerase II and the etiology of chromosomal translocations. DNA Repair (Amst.) 5: 1093-1108.
11. Joannides, M. & D. Grimwade. 2010. Molecular biology of therapy-related leukaemias. Clin. Transl. Oncol. 12: 8-14.
12. Joannides, M., A.N. Mays, A.R. Mistry, et al. 2011. Molecular pathogenesis of secondary acute promyelocytic leukemia. Mediterr. J. Hematol. Infect. Dis. 3: e2011045.
13. Cowell, I.G. & A.C. Austin. 2012. Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents. Int. J. Environ. Res. Public. Health. 9: 2075-2091.
14. Ezoe, S. 2012. Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int. J. Environ. Res. Public Health 9: 2444-2453.
15. Rashidi, A. & I.S. Fisher. 2013. Therapy-related acute promyelocytic leukemia: a systematic review. Med. Oncol. 30: 625.
16. Austin, C.A. & L.K. Marsh. 1998. Eukaryotic DNA topoisomerase IIβ. Bioessays 20: 215-226.
17. McClendon, A.K., A.C. Gentry, J.S. Dickey, et al. 2008. Bimodal recognition of DNA geometry by human topoisomerase IIα: preferential relaxation of positively supercoiled DNA requires elements in the C-terminal domain. Biochemistry 47: 13169-13178.
18. McClendon, A.K., A.C. Rodriguez & N. Osheroff. 2005. Human topoisomerase IIα rapidly relaxes positively supercoiled DNA: implications for enzyme action ahead of replication forks. J. Biol. Chem. 280: 39337-39345.
19. Woessner, R.D., M.R. Mattern, C.K. Mirabelli, et al. 1991. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 2: 209-214.
20. Christensen, M.O., M.K. Larsen, H.U. Barthelmes, et al. 2002. Dynamics of human DNA topoisomerases IIα and IIβ in living cells. J. Cell Biol. 157: 31-44.
21. Yang, X., W. Li, E.D. Prescott, et al. 2000. DNA topoisomerase IIβ and neural development. Science 287: 131-134.
22. Heng, X. & W.D. Le. 2010. The function of DNA topoisomerase IIβ in neuronal development. Neurosci. Bull. 26: 411-416.
23. Ju, B.G., V.V. Lunyak, V. Perissi, et al. 2006. A topoisomerase IIβ-mediated dsDNA break required for regulated transcription. Science 312: 1798-1802.
24. Cowell, I.G., Z. Sondka, K. Smith, et al. 2012. Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity. Proc. Natl. Acad. Sci. USA 109: 8989-8994.
25. Schoeffler, A.J. & J.M. Berger. 2008. DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Q. Rev. Biophys. 41: 41-101.
26. Schmidt, B.H., A.B. Burgin, J.E. Deweese, et al. 2010. A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases. Nature 465: 641-644.
27. Deweese, J.E. & N. Osheroff. 2010. The use of divalent metal ions by type II topoisomerases. Metallomics 2: 450-459.
28. Schmidt, B.H., N. Osheroff & J.M. Berger. 2012. Structure of a topoisomerase II-DNA-nucleotide complex reveals a new control mechanism for ATPase activity. Nat. Struct. Mol. Biol. 19: 1147-1154.
29. Bates, A.D., J.M. Berger & A. Maxwell. 2011. The ancestral role of ATP hydrolysis in type II topoisomerases: prevention of DNA double-strand breaks. Nucleic Acids Res. 39: 6327-6339.
30. Lee, S., S.R. Jung, K. Heo, et al. 2012. DNA cleavage and opening reactions of human topoisomerase IIα are regulated via Mg2+-mediated dynamic bending of gate-DNA. Proc. Natl. Acad. Sci. U.S.A. 109: 2925-2930.
31. Sander, M. & T. Hsieh. 1983. Double strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster. J. Biol. Chem. 258: 8421-8428.
32. Liu, L.F., T.C. Rowe, L. Yang, et al. 1983. Cleavage of DNA by mammalian DNA topoisomerase II. J. Biol. Chem. 258: 15365-15370.
33. Zechiedrich, E.L., K. Christiansen, A.H. Andersen, et al. 1989. Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate. Biochemistry 28: 6229-6236.
34. Pommier, Y. & C. Marchand. 2005. Interfacial inhibitors of protein-nucleic acid interactions. Curr. Med. Chem. Anti-Cancer Agents 5: 421-429.
35. Deweese, J.E., M.A. Osheroff & N. Osheroff. 2008. DNA topology and topoisomerases: teaching a "knotty" subject. Biochem. Mol. Biol. Educ. 37: 2-10.
36. Pommier, Y. 2009. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem. Rev. 109: 2894-2902.
37. Pommier, Y., E. Leo, H. Zhang & C. Marchand. 2010. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 17: 421-433.
38. Ketron, A.C. & N. Osheroff. 2013. Phytochemicals as Anticancer and Chemopreventive Topoisomerase II Poisons. In press.
39. Wu, C.C., T.K. Li, L. Farh, et al. 2011. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science 333: 459-462.
40. Wang, H., Y. Mao, A.Y. Chen, et al. 2001. Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation. Biochemistry 40: 3316-3323.
41. Lindsey, R.H., Jr., K.D. Bromberg, C.A. Felix & N. Osheroff. 2004. 1, 4-Benzoquinone is a topoisomerase II poison. Biochemistry 43: 7563-7574.
42. Bender, R.P., H.J. Lehmler, L.W. Robertson, et al. 2006. Polychlorinated biphenyl quinone metabolites poison human topoisomerase IIα: altering enzyme function by blocking the N-terminal protein gate. Biochemistry 45: 10140-10152.
43. Bender, R.P., A.J. Ham & N. Osheroff. 2007. Quinone-induced enhancement of DNA cleavage by human topoisomerase IIα: adduction of cysteine residues 392 and 405. Biochemistry 46: 2856-2864.
44. Bender, R.P. & N. Osheroff. 2007. Mutation of cysteine residue 455 to alanine in human topoisomerase IIα confers hypersensitivity to quinones: enhancing DNA scission by closing the N-terminal protein gate. Chem. Res. Toxicol. 20: 975-981.
45. Lin, R.K., N. Zhou, Y.L. Lyu, et al. 2011. Dietary isothiocyanate-induced apoptosis via thiol modification of DNA topoisomerase IIα. J. Biol. Chem. 286: 33591-33600.
46. Hasan, S.K., A.N. Mays, T. Ottone, et al. 2008. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 112: 3383-3390.
47. Errington, F., E. Willmore, M.J. Tilby, et al. 1999. Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Mol. Pharmacol. 56: 1309-1316.
48. Herzog, C.E., K.A. Holmes, L.M. Tuschong, et al. 1998. Absence of topoisomerase IIβ in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIα. Cancer Res. 58: 5298-5300.
49. Lopez-Lazaro, M., E. Willmore & C.A. Austin. 2007. Cells lacking DNA topoisomerase IIβ are resistant to genistein. J. Nat. Prod. 70: 763-767.
50. Toyoda, E., S. Kagaya, I.G. Cowell, et al. 2008. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J. Biol. Chem. 283: 23711-23720.
51. Yeh, E.T. & C.L. Bickford. 2009. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 53: 2231-2247.
52. Force, T. & K.L. Kolaja. 2011. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat. Rev. Drug. Discov. 10: 111-126.
53. Singal, P.K. & N. Iliskovic. 1998. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339: 900-905.
54. Martin, E., A.V. Thougaard, M. Grauslund, et al. 2009. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology 255: 72-79.
55. Myers, C., R. Bonow, S. Palmeri, et al. 1983. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin. Oncol. 10: 53-55.
56. Capranico, G., S. Tinelli, C.A. Austin, et al. 1992. Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim. Biophys. Acta 1132: 43-48.
57. Azarova, A.M., Y.L. Lyu, C.P. Lin, et al. 2007. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. U.S.A. 104: 11014-11019.
58. Zhang, S., X. Liu, T. Bawa-Khalfe, et al. 2012. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18: 1639-1642.
59. Ratain, M.J., L.S. Kaminer, J.D. Bitran, et al. 1987. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 70: 1412-1417.
60. DeVore, R., J. Whitlock, J.D. Hainsworth & H.D. Johnson. 1989. Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q. Ann. Intern. Med. 110: 740-742.
61. Sung, P.A., J. Libura & C. Richardson. 2006. Etoposide and illegitimate DNA double-strand break repair in the generation of MLL translocations: new insights and new questions. DNA Repair (Amst.) 5: 1109-1118.
62. Milne, T.A., S.D. Briggs, H.W. Brock, et al. 2002. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol. Cell 10: 1107-1117.
63. Hess, J.L. 2004. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol. Med. 10: 500-507.
64. Argiropoulos, B. & K.R. Humphries. 2007. Hox genes in hematopoiesis and leukemogenesis. Oncogene 26: 6766-6776.
65. Marschalek, R. 2011. Mechanisms of leukemogenesis by MLL fusion proteins. Br. J. Haematol. 152: 141-154.
66. Muntean, A.G. & L.J. Hess. 2012. The pathogenesis of mixed-lineage leukemia. Annu. Rev. Pathol. 7: 283-301.
67. Strissel, P.L., R. Strick, R.J. Tomek, et al. 2000. DNA structural properties of AF9 are similar to MLL and could act as recombination hot spots resulting in MLL/AF9 translocations and leukemogenesis. Hum. Mol. Genet. 9: 1671-1679.
68. Zhang, Y., P. Strissel, R. Strick, et al. 2002. Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia. Proc. Natl. Acad. Sci. U.S.A. 99: 3070-3075.
69. Park, S.H., H.S. Chi, Y.U. Cho, et al. 2013. Evaluation of prognostic factors in patients with therapy-related acute myeloid leukemia. Blood Res. 48: 185-192.
70. Pedersen-Bjergaard, J. & D.J. Rowley. 1994. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 83: 2780-2786.
71. Mauritzson, N., M. Albin, L. Rylander, et al. 2002. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 16: 2366-2378.
72. Kern, W., T. Haferlach, S. Schnittger, et al. 2004. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J. Clin. Oncol. 22: 2510-2511.
73. Pui, C.H., R.C. Ribeiro, M.L. Hancock, et al. 1991. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N. Engl. J. Med. 325: 1682-1687.
74. Smith, M.A., L. Rubinstein & S.R. Ungerleider. 1994. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med. Pediatr. Oncol. 23: 86-98.
75. Relling, M.V., Y. Yanishevski, J. Nemec, et al. 1998. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 12: 346-352.
76. Smith, M.A., L. Rubinstein, J.R. Anderson, et al. 1999. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J. Clin. Oncol. 17: 569-577.
77. Felix, C.A. 1998. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim. Biophys. Acta 1400: 233-255.
78. Felix, C.A. 2009. A safer regimen for high-risk neuroblastoma. Pediatr. Blood Cancer 53: 3-6.
79. Megonigal, M.D., E.F. Rappaport, D.H. Jones, et al. 1997. Panhandle PCR strategy to amplify MLL genomic breakpoints in treatment-related leukemias. Proc. Natl. Acad. Sci. U.S.A. 94: 11583-11588.
80. Robinson, B.W., N.K. Cheung, C.P. Kolaris, et al. 2008. Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome. Blood 111: 3802-3812.
81. Lovett, B.D., D. Strumberg, I.A. Blair, et al. 2001. Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry 40: 1159-1170.
82. Lovett, B.D., L. Lo Nigro, E.F. Rappaport, et al. 2001. Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. Proc. Natl. Acad. Sci. U.S. A. 98: 9802-9807.
83. Whitmarsh, R.J., C. Saginario, Y. Zhuo, et al. 2003. Reciprocal DNA topoisomerase II cleavage events at 5'-TATTA-3' sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing. Oncogene 22: 8448-8459.
84. Broeker, P.L., H.G. Super, M.J. Thirman, et al. 1996. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood 87: 1912-1922.
85. Andersen, M.K., D.H. Christiansen, B.A. Jensen, et al. 2001. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. Br. J. Haematol. 114: 539-543.
86. Felix, C.A. 2001. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med. Pediatr. Oncol. 36: 525-535.
87. Betti, C.J., M.J. Villalobos, Q. Jiang, et al. 2005. Cleavage of the MLL gene by activators of apoptosis is independent of topoisomerase II activity. Leukemia 19: 2289-2295.
88. Hars, E.S., Y.L. Lyu, C.P. Lin & L.F. Liu, 2006. Role of apoptotic nuclease caspase-activated DNase in etoposide-induced treatment-related acute myelogenous leukemia. Cancer Res. 66: 8975-8979.
89. Mirault, M.E., P. Boucher & A. Tremblay, 2006. Nucleotide-resolution mapping of topoisomerase-mediated and apoptotic DNA strand scissions at or near an MLL translocation hotspot. Am. J. Hum. Genet. 79: 779-791.
90. Stanulla, M., J. Wang, D.S. Chervinsky, et al. 1997. DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis. Mol. Cell. Biol. 17: 4070-4079.
91. Betti, C.J., M.J. Villalobos, M.O. Diaz & A.T. Vaughan. 2001. Apoptotic triggers initiate translocations within the MLL gene involving the nonhomologous end joining repair system. Cancer Res. 61: 4550-4555.
92. Le, H., S. Singh, S.J. Shih, et al. 2009. Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding. Genes Chrom. Cancer 48: 806-815.
93. van Maanen, J.M., J. Retel, deVries, J. & H.M. Pinedo. 1988. Mechanism of action of antitumor drug etoposide: a review. J. Natl. Cancer. Inst. 80: 1526-1533.
94. Relling, M.V., R. Evans, C. Dass, et al. 1992. Human cytochrome P450 metabolism of teniposide and etoposide. J. Pharmacol. Exp. Ther. 261: 491-496.
95. Relling, M.V., J. Nemec, E.G. Schuetz, et al. 1994. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol. Pharmacol. 45: 352-358.
96. Zhuo, X., N. Zheng, C.A. Felix & I.A. Blair. 2004. Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug. Metab. Dispos. 32: 993-1000.
97. Felix, C.A., A.H. Walker, B.J. Lange, et al. 1998. Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl. Acad. Sci. U.S. A. 95: 13176-13181.
98. Stremetzne, S., U. Jaehde, R. Kasper, et al. 1997. Considerable plasma levels of a cytotoxic etoposide metabolite in patients undergoing high-dose chemotherapy. Eur. J. Cancer 33: 978-979.
99. Pang, S., N. Zheng, C.A. Felix, et al. 2001. Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. J. Mass. Spectrom. 36: 771-781.
100. Stremetzne, S., U. Jaehde & W. Schunack. 1997. Determination of the cytotoxic catechol metabolite of etoposide (3'O-demethyletoposide) in human plasma by high-performance liquid chromatography. J. Chromatogr. B: Biomed. Sci. Appl. 703: 209-215.
101. Zheng, N., C.A. Felix, S. Pang, et al. 2004. Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide. Clin. Cancer Res. 10: 2977-2985.
102. Gantchev, T.G. & D.J. Hunting. 1997. Inhibition of the topoisomerase II-DNA cleavable complex by the ortho-quinone derivative of the antitumor drug etoposide (VP-16). Biochem. Biophys. Res. Commun. 237: 24-27.
103. Gantchev, T.G. & D.J. Hunting. 1998. The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex. Mol. Pharmacol. 53: 422-428.
104. Haim, N., J. Roman, J. Nemec & B.K. Sinha. 1986. Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem. Biophys. Res. Commun. 135: 215-220.
105. Jacob, D.A., S.L. Mercer, N. Osheroff & J.E. Deweese. 2011. Etoposide quinone is a redox-dependent topoisomerase II poison. Biochemistry 50: 5660-5667.
106. Kagan, V.E., J.C. Yalowich, G.G. Borisenko, et al. 1999. Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach. Mol. Pharmacol. 56: 494-506.
107. Fan, Y., E.M. Schreiber, A. Giorgianni, et al. 2006. Myeloperoxidase-catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL60 cells. Chem. Res. Toxicol. 19: 937-943.
108. Sinha, B.K., P.M. Politi, H.M. Eliot, et al. 1990. Structure-activity relations, cytotoxicity and topoisomerase II dependent cleavage induced by pendulum ring analogues of etoposide. Eur. J. Cancer 26: 590-593.
109. Osborne, C.S., L. Chakalova, K.E. Brown, et al. 2004. Active genes dynamically colocalize to shared sites of ongoing transcription. Nat. Genet. 36: 1065-1071.
110. Cook, P.R. 2010. A model for all genomes: the role of transcription factories. J. Mol. Biol. 395: 1-10.
111. Lyu, Y.L., C.P. Lin, A.M. Azarova, et al. 2006. Role of topoisomerase IIβ in the expression of developmentally regulated genes. Mol. Cell. Biol. 26: 7929-7941.
112. Gurney, J.G., J.A. Ross, D.A. Wall, et al. 1997. Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J. Pediatr. Hematol. Oncol. 19: 428-432.
113. Felix, C.A. & B.J. Lange. 1999. Leukemia in infants. Oncologist 4: 225-240.
114. Slater, D.J., E. Hilgenfeld, E.F. Rappaport, et al. 2002. MLL-SEPTIN6 fusion recurs in novel translocation of chromosomes 3, X, and 11 in infant acute myelomonocytic leukaemia and in t(X;11) in infant acute myeloid leukaemia, and MLL genomic breakpoint in complex MLL-SEPTIN6 rearrangement is a DNA topoisomerase II cleavage site. Oncogene 21: 4706-4714.
115. Eguchi, M., M. Eguchi-Ishimae & M. Greaves. 2003. The role of the MLL gene in infant leukemia. Int. J. Hematol. 78: 390-401.
116. De Braekeleer, M., F. Morel, Le Bris, et al. 2005. The MLL gene and translocations involving chromosomal band 11q23 in acute leukemia. Anticancer Res. 25: 1931-1944.
117. Megonigal, M.D., E.F. Rappaport, D.H. Jones, et al. 1998. t(11;22)(q23;q11.2) In acute myeloid leukemia of infant twins fuses MLL with hCDCrel, a cell division cycle gene in the genomic region of deletion in DiGeorge and velocardiofacial syndromes. Proc. Natl. Acad. Sci. U.S. A. 95: 6413-6418.
118. Gill Super, H.J., P.G. Rothberg, H. Kobayashi, et al. 1994. Clonal, nonconstitutional rearrangements of the MLL gene in infant twins with acute lymphoblastic leukemia: in utero chromosome rearrangement of 11q23. Blood 83: 641-644.
119. Felix, C.A., B.J. Lange, M.R. Hosler, et al. 1995. Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites. Cancer Res. 55: 4287-4292.
120. Strick, R., P.L. Strissel, S. Borgers, et al. 2000. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc. Natl. Acad. Sci. U.S. A. 97: 4790-4795.
121. Spector, L.G., Y. Xie, L.L. Robison, et al. 2005. Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the children's oncology group. Cancer Epidemiol. Biomarkers Prev. 14: 651-655.
122. Austin, C.A., S. Patel, K. Ono, et al. 1992. Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. Biochem. J. 282: 883-889.
123. Bandele, O.J. & N. Osheroff. 2007. Bioflavonoids as poisons of human topoisomerase IIα and IIβ. Biochemistry 46: 6097-6108.
124. Bandele, O.J. & N. Osheroff. 2008. (-)-Epigallocatechin gallate, a major constituent of green tea, poisons human type II topoisomerases. Chem. Res. Toxicol. 21: 936-943.
125. Bandele, O.J., S.J. Clawson & N. Osheroff. 2008. Dietary polyphenols as topoisomerase II poisons: B ring and C ring substituents determine the mechanism of enzyme-mediated DNA cleavage enhancement. Chem. Res. Toxicol. 21: 1253-1260.
126. Puumala, S.E., J.A. Ross, R. Aplenc & L.G. Spector. 2013. Epidemiology of childhood acute myeloid leukemia. Pediatr. Blood Cancer 60: 728-733.
127. de The, H., C. Chomienne, M. Lanotte, et al. 1990. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347: 558-561.
128. Kakizuka, A., W.H. Miller, Jr., K. Umesono, et al. 1991. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 66: 663-674.
129. Reiter, A., S. Saussele, D. Grimwade, et al. 2003. Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. Genes Chromosomes Cancer 36: 175-188.
130. Beaumont, M., M. Sanz, P.M. Carli, et al. 2003. Therapy-related acute promyelocytic leukemia. J. Clin. Oncol. 21: 2123-2137.
131. Salomoni, P. & J. Betts-Henderson. 2011. The role of PML in the nervous system. Mol. Neurobiol. 43: 114-123.
132. Pinton, P., C. Giorgi & P.P. Pandolfi. 2011. The role of PML in the control of apoptotic cell fate: a new key player at ER-mitochondria sites. Cell Death Differ. 18: 1450-1456.
133. Chen, R.H., Y.R. Lee & W.C. Yuan 2012. The role of PML ubiquitination in human malignancies. J. Biomed. Sci. 19: 81.
134. de The, H., Le Bras, M. & V. Lallemand-Breitenbach. 2012. The cell biology of disease: acute promyelocytic leukemia, arsenic, and PML bodies. J. Cell. Biol. 198: 11-21.
135. Takahashi, Y., V. Lallemand-Breitenbach, J. Zhu & H. de The. 2004. PML nuclear bodies and apoptosis. Oncogene 23: 2819-2824.
136. Bernardi, R. & P.P. Pandolfi. 2007. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell. Biol. 8: 1006-1016.
137. Lallemand-Breitenbach, V. & H. de The. 2010. PML nuclear bodies. Cold Spring Harb. Perspect. Biol. 2: a000661.
138. de The, H. & Z. Chen. 2010. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat. Rev. Cancer. 10: 775-783.
139. Hillestad, L.K. 1957. Acute promyelocytic leukemia. Acta. Med. Scand. 159: 189-194.
140. Warrell, R.P., Jr., H. de The, Z.Y. Wang & L. Degos. 1993. Acute promyelocytic leukemia. N. Engl. J. Med. 329: 177-189.
141. Mistry, A.R., E.W. Pedersen, E. Solomon & D. Grimwade. 2003. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev. 17: 71-97.
142. Wang, Z.Y. & Z. Chen. 2008. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111: 2505-2515.
143. Mistry, A.R., C.A. Felix, R.J. Whitmarsh, et al. 2005. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N. Engl. J. Med. 352: 1529-1538.
144. Mays, A.N., N. Osheroff, Y. Xiao, et al. 2010. Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. Blood 115: 326-330.
145. Ellis, R.J., S. Brown & M. Boggild. 2013. Therapy related acute leukaemia with mitoxantrone: 4 years on, what is the risk and can it be limited? J. Neurol. Neurosurg. Psychiatr. 84: e2.
146. Ghalie, R.G., E. Mauch, G. Edan, et al. 2002. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult. Scler. 8: 441-445.
147. Fortune, J.M. & N. Osheroff. 2000. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog. Nucleic Acid Res. Mol. Biol. 64: 221-253.
148. Wray, J., E.A. Williamson, S.B. Singh, et al. 2013. PARP1 is required for chromosomal translocations. Blood 121: 4359-4365.
149. Wang, M., W. Wu, B. Rosidi, et al. 2006. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 34: 6170-6182.